Market Overview

XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides Update

Share:

XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides Update

PR Newswire

RAMAT GAN, Israel, July 24, 2018 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced financial results for the quarter ended June 30, 2018 and provided an update on the development program for its lead drug candidate hCDR1.

The Company is expanding its IP portfolio surrounding hCDR1 and has decided to reduce its research and development expenditures in connection with execution of its clinical trials. In parallel, the Company searches to identify additional assets to add to XTL's portfolio.

Financial Overview

XTL reported approximately $1.1 million in cash and cash equivalents as of June 30, 2018 and approximately $5 million in Other Current Assets (mainly short term bank deposits). The decrease of $2.2 million since December 31, 2017, in cash and cash equivalents derives mainly from depositing additional $1.8 million to the short-term bank deposit.

Research and development expenses for the six months ended June 30, 2018 were $20 thousand compared to $38 thousand for the corresponding period in 2017. The decrease was due to management decision to reduce its research and development expenditures on its current drug.

General and administrative expenses for the six months ended June 30, 2018 were $362 thousand compared to $732 thousand for the corresponding period in 2017. The change resulted mainly from decreases in salaries and expenses relating to employees (including stock-based compensation expenses) and investor relations.

Finance income, net for the six months ended June 30, 2018 were $1,291 thousand compared to finance expenses, net amounted to $1,595 thousand for the corresponding period in 2017. The difference is driven primarily by revaluation of warrants. During the first quarter of 2018 the Company filed an F-1 amendment and registered its warrants. Subsequently, all warrants were classified to the capital and there will be no further future evaluations. Another reason for the difference is the revaluation of marketable securities (investment in stocks of InterCure Ltd.).

XTL reported an operating loss for the six months ended June 30, 2018 of $382 thousand compared to $770 thousand for the corresponding period in 2017 reflecting decreased spending on research and development and general and administrative expenses. The Company reported a total net income for the period ended June 30, 2018 of approximately $909 thousand or $0.002 per share, compared to a loss of  approximately $2,403 thousand or $0.006 per share in the corresponding period in 2017.  The change is driven primarily by the revaluation of warrants as described above.


 

XTL Biopharmaceuticals, Ltd. and Subsidiaries

(USD in thousands)

Consolidated Statements of Financial Position - Selected Data








As of


As of



June 30,


December 31,



2018


2017

Cash, cash equivalents


$              1,135


$              3,289

Short-term deposit


4,323


2,507

Other current assets


598


410

Non-current assets


380


380

Total assets


6,436


6,586






Current liabilities


$                 198


$                 300

Non-current liabilities


-


2,667

Total shareholders' equity


6,238


3,619

Total liabilities and shareholders' equity


6,436


6,586

 

 

XTL Biopharmaceuticals, Ltd. and Subsidiaries

(USD in thousands, except per share amounts)

Consolidated Statements of Comprehensive Income - Selected Data




For the six months ended

June 30,


2018


2017





Research and Development expenses

$                 (20)


$                 (38)

General and administrative expenses

(362)


(732)

Operating Loss

$               (382)


$               (770)





Finance income

$              1,319


$                   24

Finance expenses

(28)


(1,619)

Finance income (expenses), net

$               1,291


$          (1,595)





Total income (loss)

$                  909


$            (2,365)





Other comprehensive income:




Items that may be reclassified to profit or loss:




Changes in the fair value of available-for-sale financial assets

$                      -


$                (38)

Other comprehensive income

$                      -


View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com